Cuddihy R M, Bahn R S
Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA.
J Clin Endocrinol Metab. 1996 Dec;81(12):4476-8. doi: 10.1210/jcem.81.12.8954062.
Although an association between the human leukocyte antigen (HLA) allele DR3 and Graves' disease (GD) is well documented, the potential role of non-HLA-linked alleles in susceptibility to GD is an area of active investigation. In an attempt to study the potential role of two non-HLA susceptibility alleles in GD and Graves' ophthalmopathy, we examined 286 North American Caucasian individuals (145 normal controls and 141 individuals with GD) for the presence of the A2 allele of the interleukin-1 (IL-1) receptor antagonist gene. In addition, we examined a subset of this population (83 normal controls and 89 individuals with GD) for a specific polymorphism within exon 5 of the IL-1 alpha gene. We found the A2 allelic frequencies (0.25 and 0.23, respectively) and carriage rates (43% and 41%, respectively) in the two groups to be nearly identical. However, findings in the subgroup of patients with the extrathyroidal manifestations of GD (Graves' ophthalmopathy, pretibial dermopathy, and acropachy) suggested a trend toward a higher prevalence of the A2 allele in patients with more severe disease. The allelic frequency (0.28) and carriage rate (47%) of the IL-1 alpha exon 5 polymorphism in individuals with GD were nearly identical to those of the control population (0.28% and 45%, respectively). In summary, we were unable to demonstrate an association between these alleles and GD in our study population. We conclude that neither the A2 allele of the IL-1 receptor antagonist gene nor the IL-1 alpha exon 5 polymorphism confers increased susceptibility to GD.
尽管人类白细胞抗原(HLA)等位基因DR3与格雷夫斯病(GD)之间的关联已有充分记录,但非HLA连锁等位基因在GD易感性中的潜在作用仍是一个活跃的研究领域。为了研究两个非HLA易感等位基因在GD和格雷夫斯眼病中的潜在作用,我们检测了286名北美白种人个体(145名正常对照者和141名GD患者)白细胞介素-1(IL-1)受体拮抗剂基因A2等位基因的存在情况。此外,我们还检测了该人群中的一个亚组(83名正常对照者和89名GD患者)IL-1α基因第5外显子内的一个特定多态性。我们发现两组的A2等位基因频率(分别为0.25和0.23)和携带率(分别为43%和41%)几乎相同。然而,GD有甲状腺外表现(格雷夫斯眼病、胫前皮肤病变和杵状指)的患者亚组研究结果表明,病情越严重的患者中A2等位基因的患病率有升高趋势。GD患者中IL-1α第5外显子多态性的等位基因频率(0.28)和携带率(47%)与对照人群(分别为0.28%和45%)几乎相同。总之,在我们的研究人群中,我们未能证明这些等位基因与GD之间存在关联。我们得出结论,IL-1受体拮抗剂基因的A2等位基因和IL-1α第5外显子多态性均未增加GD的易感性。